A detailed history of Stifel Financial Corp transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Stifel Financial Corp holds 27,619 shares of ADAP stock, worth $26,238. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,619
Previous 23,797 16.06%
Holding current value
$26,238
Previous $37,000 27.03%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.83 - $1.47 $3,172 - $5,618
3,822 Added 16.06%
27,619 $27,000
Q1 2024

May 13, 2024

SELL
$0.7 - $1.75 $2,423 - $6,058
-3,462 Reduced 12.7%
23,797 $37,000
Q4 2023

Feb 12, 2024

SELL
$0.43 - $0.79 $1,106 - $2,033
-2,574 Reduced 8.63%
27,259 $21,000
Q1 2023

May 12, 2023

SELL
$1.06 - $2.16 $901 - $1,836
-850 Reduced 2.77%
29,833 $32,000
Q4 2022

Feb 13, 2023

BUY
$1.05 - $2.53 $1,207 - $2,909
1,150 Added 3.89%
30,683 $44,000
Q3 2022

Nov 14, 2022

SELL
$1.06 - $2.41 $128 - $291
-121 Reduced 0.41%
29,533 $32,000
Q1 2022

May 13, 2022

SELL
$1.73 - $4.06 $14,705 - $34,510
-8,500 Reduced 22.28%
29,654 $61,000
Q4 2021

Feb 14, 2022

SELL
$3.5 - $5.68 $21,150 - $34,324
-6,043 Reduced 13.67%
38,154 $143,000
Q3 2021

Nov 15, 2021

BUY
$3.44 - $6.37 $2,917 - $5,401
848 Added 1.96%
44,197 $229,000
Q2 2021

Aug 13, 2021

BUY
$3.86 - $5.78 $37,580 - $56,274
9,736 Added 28.96%
43,349 $185,000
Q1 2021

May 14, 2021

BUY
$4.9 - $6.83 $14,636 - $20,401
2,987 Added 9.75%
33,613 $178,000
Q4 2020

Feb 12, 2021

SELL
$4.0 - $9.2 $543,356 - $1.25 Million
-135,839 Reduced 81.6%
30,626 $165,000
Q3 2020

Nov 16, 2020

BUY
$7.66 - $10.78 $1.16 Million - $1.63 Million
151,031 Added 978.56%
166,465 $1.33 Million
Q2 2020

Aug 14, 2020

BUY
$2.58 - $12.1 $39,819 - $186,751
15,434 New
15,434 $154,000
Q4 2018

Feb 13, 2019

SELL
$3.76 - $14.16 $341,618 - $1.29 Million
-90,856 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$8.27 - $13.56 $751,379 - $1.23 Million
90,856 New
90,856 $1.22 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $155M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.